DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
For several years, the effective standard induction chemotherapy for AML has been limited to
the association of anthracycline and aracytine. GO is the first effective targeted antibody
used in leukemia patients. In a previous study, we showed efficacy and safety of fractionated
doses of GO used as a single agent for treatment of adult AML patients in first relapse. In
the present study the possibility of combining fractionated doses of GO to escalated doses of
a 3+7 regimen old is studied in relapsed AML patients > 50 and <70 years.